AMD

AMD
Coolcaesar · CC BY-SA 4.0 · source
Name	Age-related macular degeneration
Field	Ophthalmology
Synonyms	Senile macular degeneration
Symptoms	Central vision loss, metamorphopsia, scotoma
Complications	Visual impairment, legal blindness
Onset	Older adulthood
Types	Dry (atrophic), Wet (neovascular)

AMD

Age-related macular degeneration is a progressive retinal disorder causing central vision loss in older adults. It primarily affects the macula of the retina and leads to impairment in tasks such as reading, driving, and recognizing faces. Management spans lifestyle modification, pharmacotherapy, and surgical interventions within clinical frameworks from organizations such as the World Health Organization and specialty societies including the American Academy of Ophthalmology.

Overview

AMD is characterized by degeneration of the macula, a specialized region of the retina responsible for high-acuity vision and color perception. Pathological hallmarks include drusen accumulation beneath the retinal pigment epithelium and disruption of the photoreceptor–RPE–choriocapillaris complex, processes studied in laboratories associated with institutions like the National Institutes of Health and universities such as Johns Hopkins University and University College London. Clinical practice guidelines from bodies including the Royal College of Ophthalmologists inform screening and management.

Types and Pathophysiology

Two principal forms are described: dry (atrophic) AMD with geographic atrophy and wet (neovascular) AMD with choroidal neovascularization. Dry AMD features drusen deposits and RPE atrophy, processes investigated in experimental models at the Salk Institute and Massachusetts Institute of Technology. Wet AMD involves abnormal vessel growth from the choroid through Bruch’s membrane, mediated by angiogenic factors such as vascular endothelial growth factor targeted by therapies developed by companies like Genentech and studied in trials run by groups including the European Society of Retina Specialists. Genetic contributors include variants in genes such as CFH and ARMS2 discovered in cohorts coordinated by centers like the Broad Institute and Karolinska Institutet. Inflammatory and complement pathways studied at the Ludwig Institute for Cancer Research and the Max Planck Society also contribute to pathogenesis.

Risk Factors and Prevention

Major risk factors encompass increasing age and genetic predisposition identified through genome-wide association studies by consortia such as the International AMD Genomics Consortium. Environmental and lifestyle risks include smoking exposure highlighted in research by Centers for Disease Control and Prevention, dietary patterns examined in studies from the Harvard T.H. Chan School of Public Health, and cardiovascular comorbidity clusters evaluated in cohorts like the Framingham Heart Study. Preventive strategies promoted by public health agencies including the National Health Service emphasize smoking cessation, dietary modification (omega-3 and antioxidant intake studied in the Age-Related Eye Disease Study), and regular ophthalmic surveillance conducted in clinics affiliated with academic hospitals such as Mayo Clinic.

Diagnosis

Diagnosis relies on clinical examination and multimodal imaging in ophthalmic centers like the Bascom Palmer Eye Institute and diagnostic companies including Carl Zeiss Meditec. Visual acuity testing, Amsler grid screening, fundus photography, optical coherence tomography performed with devices from Heidelberg Engineering, and fluorescein angiography remain standard. Biomarkers and genetic testing panels offered by laboratories such as Mayo Clinic Laboratories and research centers including Stanford University augment risk stratification. Diagnostic algorithms are reflected in practice statements from the American Academy of Ophthalmology and consensus guidelines from the European Society of Retina Specialists.

Treatment and Management

Management differs by subtype: dry AMD focuses on risk-reduction and supportive measures, referencing evidence from the Age-Related Eye Disease Study and recommendations by the Royal College of Ophthalmologists. Wet AMD treatment centers on intravitreal anti-VEGF agents developed and marketed by firms like Regeneron Pharmaceuticals and Novartis, with treatment protocols established through randomized trials at institutions such as Wills Eye Hospital and regulatory approvals by agencies like the Food and Drug Administration. Adjunctive approaches include photodynamic therapy used historically at centers such as Bascom Palmer Eye Institute and low-vision rehabilitation services coordinated by organizations like Lighthouse Guild and Royal National Institute of Blind People.

Epidemiology

Prevalence and burden estimates derive from global analyses by the World Health Organization and large population studies including the Blue Mountains Eye Study and Beaver Dam Eye Study. AMD is a leading cause of irreversible central vision loss in high-income regions such as North America and Western Europe, with rising prevalence projected by demographic models from agencies like the United Nations due to population aging. Economic impact assessments have been conducted by health economics groups at institutions like Imperial College London and Johns Hopkins Bloomberg School of Public Health.

Research and Future Directions

Active research domains include complement-inhibition therapeutics trialed in multicenter studies coordinated by consortia such as the European Foundation for the Study of AMD, gene therapy approaches developed at centers like University of Pennsylvania and biotechnology firms, and sustained-release drug delivery systems engineered by collaborations between Massachusetts Institute of Technology and industry partners. Imaging advances from companies like Topcon Corporation and artificial intelligence algorithms validated at Google Health and academic centers aim to improve screening and prognostication. Large-scale registries and randomized trials led by organizations such as the National Eye Institute continue to refine prevention and treatment paradigms.

Category:Ophthalmology